Long-term effects of lercanidipine on the lipoprotein and apolipoprotein profile of patients with mild-to-moderate essential hypertension

1998, Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other societies on coronary prevention, Eur Heart J, 19, 1434, 10.1053/euhj.1998.1243 1997, The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure, Arch Intern Med, 157, 2413, 10.1001/archinte.1997.00440420033005 Lardinois, 1988, The effects of antihypertensive agents on serum lipids and lipoproteins, Arch Intern Med, 148, 1280, 10.1001/archinte.1988.00380060044012 Collins, 1990, Blood pressure, stroke coronary heart disease. Part 2. Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context, Lancet, 335, 827, 10.1016/0140-6736(90)90944-Z Davis, 1996, Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), Am J Hypertens, 9, 342, 10.1016/0895-7061(96)00037-4 Zanchetti, 1996, Trials investigating the anti-atherosclerotic effects of antihypertensive drugs, J Hypertens, 14, 77, 10.1097/00004872-199609002-00015 Malini, 1995, Amlodipine, Drugs, 50, 560, 10.2165/00003495-199550030-00009 Nielsen, 1992, Effects on plasma lipids during long term antihypertensive treatment with felodipine, Drug Invest, 4, 361, 10.1007/BF03258412 Schulte, 1986, Antihypertensive and metabolic effects of diltiazem and nifedipine, Hypertension, 8, 859, 10.1161/01.HYP.8.10.859 Policicchio, 1997, Efficacy and tolerability of lercanidipine in patients with mild to moderate essential hypertension: A comparative study with slowrelease nifedipine, J Cardiovasc Pharmacol, 29, S31, 10.1097/00005344-199729002-00006 Cafiero, 1997, Long-term (12 month) treatment with lercanidipine in patients with mild to moderate hypertension, J Cardiovasc Pharmacol, 29, S45, 10.1097/00005344-199729002-00009 Paterna, 1997, Lercanidipine in two different dosage regimens as a sole treatment for severe essential hypertension, J Cardiovasc Pharmacol, 29, S50, 10.1097/00005344-199729002-00010 Roschlau, 1974, Enzymatische bestimmung des gesamtecholesterins in serum, Z Klin Chem Klin Biochem, 12, 403 Wahlefeld, 1974, Triglycerides. Determination after enzymatic hydrolysis, 1831 Lopez-Virella, 1970, Cholesterol determination in the HDL separated by precipitation with polianions, J Lipid Res, 11, 583 Friedewald, 1972, Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge, Clin Chem, 18, 499, 10.1093/clinchem/18.6.499 Becker, 1980, Standardization of immunochemical quantitation of human apolipoprotein A and B, La Ricerca in Clinica e Laboratorio, 10, 203, 10.1007/BF02984927 Ames, 1991, Hyperlipidemia in hypertension: Causes and prevention, Am Heart J, 122, 1219, 10.1016/0002-8703(91)90943-C